Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.

Oncology reports - 1 Jan 2008

Taguchi Takahide, Tsukuda Mamoru, Imagawa-Ishiguro Yukari, Kato Yasumasa, Sano Daisuke

Abstract excerpt

Epidermal growth factor receptor (EGFR) gene mutations are associated with the sensitivity of non-small cell lung carcinomas (NSCLCs) to gefitinib, but such findings have not been reported in squamous cell carcinomas of the head and heck (SCCHNs). Accordingly, we determined whether EGFR gene expression and mutations correlate with the in vitro efficacy of gefitinib in SCCHN cell lines. EGFR status was analyzed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gefitinib

Share to Head and Neck Neoplasms

Share to Inhibitory Concentration 50

Share to Quinazolines

Source

Identifiers

PMID: 18097577

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.PMID 18097577Read ↗

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.Semantic proximity Read ↗

Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.Semantic proximity Read ↗

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.Semantic proximity Read ↗

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSemantic proximity Read ↗

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).Semantic proximity Read ↗

Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma.Semantic proximity Read ↗

EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.Semantic proximity Read ↗

Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinomaSemantic proximity Read ↗

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.